<DOC>
	<DOC>NCT00484094</DOC>
	<brief_summary>To provide safety and effectiveness information for Rapamune during the post-marketing period as required by Korea Food and Drug Administration (KFDA) regulations in order to identify any potential drug related treatment factors in the Korean population, such as: 1. Unknown adverse reactions, especially serious adverse reactions 2. To assess the incidence of adverse reactions under the routine drug uses 3. Factors that may affect the safety of the drug (e.g., proteinuria) 4. Factors that may affect the effectiveness of the drug</brief_summary>
	<brief_title>Study Investigating Rapamune For Post-Marketing Surveillance</brief_title>
	<detailed_description>All patients who receive Rapamune for certain period of time should be included as far as patients consent to participate</detailed_description>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Subjects aged 13 years or older receiving renal transplants, who are newly administered Rapamune after a contract is made between Pfizer Korea and an investigator and/or an institution for conducting this study. Any patient who does not agree that Pfizer and companies working with Pfizer use his/her information. Patients who have known hypersensitivity to Rapamune or its derivatives or any excipients in the formulation.</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Rapamune</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Kidney Transplantation</keyword>
</DOC>